SCHEMBL14082240

SCHEMBL14082240

Cc1c(Br)cc(/C=N/NC(=O)CNc2ccc3cc4ccccc4cc3c2)cc1Br

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.63
▸ KMT2A Q03164 8/20 0.63
▸ MAPT P10636 12/20 0.62
▸ ALDH1A1 P00352 5/20 0.62
▸ KDM4E B2RXH2 3/20 0.62
▸ CFTR P13569 1/20 0.61
▸ TDP1 Q9NUW8 2/20 0.57
▸ GAA P10253 2/20 0.56
▸ POLB P06746 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ HTT P42858 1/20 0.53
▸ LMNA P02545 3/20 0.53
▸ MITF O75030 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ XBP1 P17861 1/20 0.50
▸ GRK2 P25098 2/20 0.49
▸ ERCC1 P07992 1/20 0.48
▸ ERCC4 Q92889 1/20 0.48
▸ LIG1 P18858 2/20 0.48
▸ LIG3 P49916 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14082217 0.97 MEN1 (0.67) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL12648544 0.90 CFTR (0.72) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL12648528 0.87 CFTR (0.77) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL14082244 0.85 CFTR (0.78) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL12671818 0.82 CFTR (0.70) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL14082216 0.82 CFTR (0.83) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL14082228 0.82 GRK2 (0.63) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL12648541 0.82 MAPT (0.77) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL14082235 0.82 MAPT (0.78) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL14082221 0.80 MAPT (0.66) MEN1KMT2AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414037-B2 cystic fibrosis transmembrane conductance regulator protein inhibitor; 2-naphthalenylamino-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene][3-[4-(3-(PEG)n-thioureido)diphenyl)-thioureido]propanedioic acid dihydrazide (MalH-(PEG)nB); cystic fibrosis with forms of male infertility, secretory diarrhea THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-08-19 — — US disclosed
Send feedback